- Home
- OBE vs KMDA Comparison
OBE vs KMDA Comparison
Compare OBE & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | KMDA |
|---|---|---|
| Founded | 1979 | 1990 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.9M | 458.6M |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OBE | KMDA |
|---|---|---|
| Price | $8.50 | $8.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 533.5K | 66.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | $20.21 | $11.38 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.88 | $5.54 |
| 52 Week High | $8.85 | $9.35 |
Technical Indicators
Market Signals| Indicator | OBE | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 64.74 | 57.85 |
| Support Level | $5.57 | $6.69 |
| Resistance Level | N/A | $9.35 |
| Average True Range (ATR) | 0.41 | 0.27 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 79.31 | 72.63 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.